NASH PRECLINICAL CRO SERVICES
The increase in the global prevalence of NASH (Non-Alcoholic Steatohepatitis) has turned into an epidemic, urgently requiring effective therapies. Physiogenex provides high quality NASH preclinical CRO services in order to help clients develop new treatments for NASH and liver fibrosis. We provide outstanding scientific expertise, unique in vivo NASH models and golden standards in NASH biomarkers, histology analysis and blinded NAS scoring.
As a pioneer preclinical CRO in the NASH and liver fibrosis field, we help our clients to move forward quickly with their drug candidates. We deliver original, diet-induced and benchmarked animal models of human NAFLD/NASH to evaluate novel drugs efficacy. Our very fast (3 to 8 weeks) NASH models allow to rapidly demonstrate the potency of our clients’ compounds. To further confirm the drug efficacy, diet-induced NASH models with concomitant obesity, insulin resistance and dyslipidaemia can be used.
In each NASH model, client drugs can be compared with clinical benchmarks: elafibranor, obeticholic acid and liraglutide.
NASH in vivo disease models
NASH preclinical CRO services
Biochemistry assays and histology
Gene expression (qPCR), plasma ALT/AST follow-up, bile acids
Biochemistry/biomarkers: liver inflammation biomarkers, liver enzymes, collagen hyaluronic acid, lipids
- Body weight, food intake, lipid homeostasis, blood collection and tissue harvesting
- Histopathology analysis and NAFLD activity score (NAS)
Histology analysis: ORO, H&E, Sirius Red, Masson Trichrom
Immunohistochemistry: F4/80, α-SMA
In vivo drug efficacy studies
In vivo lipogenesis
Complementary techniques associated with diabetes and insulin resistance: glucose homeostasis
Complementary techniques associated with lipid disorders: lipid metabolism
Our major scientific publications on NASH
- “Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model”,
Briand F, Brousseau E, Quinsat M, Burcelin R, Sulpice T. Eur J Pharmacol. 2018 Jan 5;818:449-456
- “Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of non-alcoholic steatohepatitis.
Duparc T, Briand F, Trenteseaux C, Mérian J, Combes G, Najib S, Sulpice T, Martinez L, .
CONTACT US FOR MORE INFORMATION